Journey Medical Corporation

Scottsdale, United States · Biotechnology, Healthcare, Health Care · 73 employees

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and hea

Funding history

Funding Round — $19.0M — Oct 2021
Funding Round — $19.0M — Sep 2021

Recent signals

Apr 21, 2026: SEC 8-K (8.01): On April 21, 2026, Journey Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™, which includes 40 mg Minocycline Hydrochloride Modified-Release Capsules and a combination of 10 mg immediate release and 30 mg extended release formulations. This expansion is significant as it enhances patient access to the treatment for inflammatory lesions of rosacea in adults. The filing includes a press release detailing the coverage expansion, emphasizing the company's commitment to improving health outcomes for patients requiring this treatment. This event reflects a strategic initiative to broaden the market reach and adoption of their product.
Apr 01, 2025: Journey Medical Promotes Ramsey Alloush to Chief Operating Officer
Nov 04, 2024: Launched Journey Medical Corporation announces the FDA approval of Emrosi™ for treating rosacea, providing a new option for patients in the U.S.
May 01, 2024: Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer
Oct 05, 2021: Raised $19.0M
Sep 22, 2021: Raised $19.0M

See plans & pricing → Track Journey Medical Corporation’s funding, hiring, and signals — with verified contacts — on Fundz.